An analysis of baseline data from the PROUD study: an open-label randomised trial of pre-exposure prophylaxis
Authors:
- On behalf of the PROUD Study GroupOGOn behalf of the PROUD Study Group
- David I. DollingDDDavid I. Dolling
- Monica DesaiMDMonica Desai
- Alan McOwanAMAlan McOwan
- Richard GilsonRGRichard Gilson
- Amanda ClarkeACAmanda Clarke
- Martin FisherMFMartin Fisher
- Gabriel SchembriGSGabriel Schembri
- Ann K. SullivanASAnn K. Sullivan
- Nicola MackieNMNicola Mackie
- Iain ReevesIRIain Reeves
- Mags PortmanMPMags Portman
Open Access
- 24 March 2016
- journal article
- research article
- Published by Springer Nature in Trials
- Vol. 17 (1) , 163
Abstract
Pre-exposure prophylaxis (PrEP) has proven biological efficacy to reduce the sexual acquisition of the human immunodeficiency virus (HIV). The PROUD study found that PrEP conferred higher protection than in placebo-controlled trials, reducing HIV incidence by 86 % in a population with seven-fold higher HIV incidence than expected. We present the baseline characteristics of the PROUD study population and place the findings in the context of national sexual health clinic data. The PROUD study was designed to explore the real-world effectiveness of PrEP (tenofovir-emtricitabine) by randomising HIV-negative gay and other men who have sex with men (GMSM) to receive open-label PrEP immediately or after a deferral period of 12 months. At enrolment, participants self-completed two baseline questionnaires collecting information on demographics, sexual behaviour and lifestyle in the last 30 and 90 days. These data were compared to data from HIV-negative GMSM attending sexual health clinics in 2013, collated by Public Health England using the genitourinary medicine clinic activity database (GUMCAD). The median age of participants was 35 (IQR: 29–43). Typically participants were white (81 %), educated at a university level (61 %) and in full-time employment (72 %). Of all participants, 217 (40 %) were born outside the UK. A sexually transmitted infection (STI) was reported to have been diagnosed in the previous 12 months in 330/515 (64 %) and 473/544 (87 %) participants reported ever having being diagnosed with an STI. At enrolment, 47/280 (17 %) participants were diagnosed with an STI. Participants reported a median (IQR) of 10 (5–20) partners in the last 90 days, a median (IQR) of 2 (1–5) were condomless sex acts where the participant was receptive and 2 (1–6) were condomless where the participant was insertive. Post-exposure prophylaxis had been prescribed to 184 (34 %) participants in the past 12 months. The number of STI diagnoses was high compared to those reported in GUMCAD attendees. The PROUD study population are at substantially higher risk of acquiring HIV infection sexually than the overall population of GMSM attending sexual health clinics in England. These findings contribute to explaining the extraordinary HIV incidence rate during follow-up and demonstrate that, despite broad eligibility criteria, the population interested in PrEP was highly selective. Current Controlled Trials ISRCTN94465371 . Date of registration: 28 February 2013.Keywords
This publication has 25 references indexed in Scilit:
- HIV Incidence Among Men With and Those Without Sexually Transmitted Rectal Infections: Estimates From Matching Against an HIV Case RegistryClinical Infectious Diseases, 2013
- The Cost and Impact of Scaling Up Pre-exposure Prophylaxis for HIV Prevention: A Systematic Review of Cost-Effectiveness Modelling StudiesPLOS Medicine, 2013
- The Potential Impact of Pre-Exposure Prophylaxis for HIV Prevention among Men Who Have Sex with Men and Transwomen in Lima, Peru: A Mathematical Modelling StudyPLOS Medicine, 2012
- Maintaining cost-effective access to antiretroviral drug therapy through a collaborative approach to drug procurement, consensus treatment guidelines and regular audit: the experience of London HIV commissioners and providersSexually Transmitted Infections, 2012
- Pre-Exposure Prophylaxis and Antiretroviral Resistance: HIV Prevention at a Cost?Clinical Infectious Diseases, 2011
- Number of casual male sexual partners and associated factors among men who have sex with men: Results from the National HIV Behavioral Surveillance systemBMC Public Health, 2011
- Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with MenNew England Journal of Medicine, 2010
- Preexposure Prophylaxis and Predicted Condom Use Among High-Risk Men Who Have Sex With MenJAIDS Journal of Acquired Immune Deficiency Syndromes, 2010
- HIV Preexposure Prophylaxis in the United States: Impact on Lifetime Infection Risk, Clinical Outcomes, and Cost‐EffectivenessClinical Infectious Diseases, 2009
- The PHQ-9Journal of General Internal Medicine, 2001